Aptamer Group reports progress in partnerships and growth strategy at AGM

Aptamer Group

Aptamer Group plc (LON:APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, will hold its Annual General Meeting (AGM) at 10:00 am today at the offices of Aptamer Group, Windmill House, Innovation Way, York, YO10 5BR.

Dr Adam Hargreaves, Non-Executive Chairman will provide the following statement:

“I am delighted with the progress made by Aptamer Group. Since the fundraising of £2.6m in July this year, we have met our cost-base reduction targets, streamlined our scientific production capabilities, and executed our new commercial growth strategy to deliver optimised products of high quality to our growing customer base.

Attracting new partners has ensured that we are now working with the majority of the larger global pharmaceutical companies, alongside a wealth of diagnostic, healthcare, and niche biotech partners. Particular highlights have included the development of a vertical market platform in fibrosis, in which we are working with AstraZeneca; the progression toward human trials of our deodorant Optimer product with Unilever; and the successful production of an Optimer delivery conjugate to an undisclosed genetic medicines company, with which they are planning pre-clinical trials.

Our increased commercial traction has secured newly signed contracts, currently up to the value of £471,000, which will ensure that the Group’s cash runway remains generous, allowing any licensing opportunities to evolve and potentially crystalise over this extended period.

The Board looks forward to updating shareholders on further progress in due course.”

The AGM will provide no new material information. Results of the AGM will be announced to the London Stock Exchange and placed on the Aptamer Group’s website, in the usual way, as soon as practicable after the conclusion of the AGM.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

    Aptamer Group extends Unilever collaboration for deodorant Optimers

    Aptamer Group has secured additional paid work from Unilever under their existing collaboration, advancing Optimers as deodorant actives with expanded stability testing ahead of on‑person trials.

    Aptamer Group raises £2.0 million in share placing

    Aptamer has raised £2.0 million (before expenses) by placing 666,666,666 new ordinary shares at 0.3 p each, representing 25.1 per cent of its enlarged issued share capital. The proceeds will accelerate commercialisation of the Optimer® platform, support in-house manufacturing, launch new biomarker services and develop AI-driven aptamer discovery.

    Aptamer Group raises £2m to fund growth

    Aptamer Group plc has raised £2.0 million (before expenses) via a placing of new ordinary shares at 0.3p per share, representing a 21.1% discount.

    Aptamer advances liver fibrosis therapy with targeted gene delivery

    Aptamer Group has identified a novel target using its Optimer® platform to deliver gene therapy directly to liver scarring cells.

    Aptamer signs licensing deal for Optimer®-Fc diagnostic reagent

    Aptamer Group has entered a funded development and licensing agreement with a global life sciences company to create an Optimer®-Fc reagent for diagnostic kits. The deal includes royalties on future sales, supporting Aptamer’s recurring revenue growth.

    Aptamer expands odour control collaboration with Unilever

    Aptamer Group plc has partnered with Unilever for a second Optimer program, aiming to innovate body odour control solutions in the personal care market.

      Search

      Search